Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Axitinib ed etoposide metronomico orale per bambini pediatrici e medulloblastoma ed ependimoma refrattari/recidivanti AYA (MEPENDAX)

9 novembre 2026 aggiornato da: Assistance Publique Hopitaux De Marseille

MEPENDAX: studio di fase I/II su axitinib (Inlyta®) ed etoposide metronomico orale per bambini pediatrici e medulloblastoma ed ependimoma refrattari/recidivanti AYA

It is an open multicentric phase I/II trial with axitinib (Inlyta®) and metronomic delivery of etoposide for children, adolescent and young adults (AYA) with refractory/ relapsing solid tumors. It is a two-stage trial:

First stage: To determine the Maximum Tolerated Dose (MTD) of the combination of axitinib and oral metronomic etoposide for patient with medulloblastoma or ependymoma Second stage: Extension cohort evaluating the preliminary efficacy at the recommended dose for the phase II (RDP2) of the combination. The 2nd stage will start after a meeting of independent data monitoring committee (IDMC). Two cohorts of 9 patients with ependymoma and medulloblastoma Patients treated at first stage won't be included in the second stage.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

40

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

      • Angers, Francia
        • Reclutamento
        • Centre Hospitalier Universitaire D'Angers
        • Contatto:
      • Bordeaux, Francia
        • Reclutamento
        • Centre Hospitalier Universitaire De Bordeaux
        • Contatto:
      • Lyon, Francia
        • Reclutamento
        • IHOPe Institut d'Hématologie et d'Oncologie Pédiatrique
        • Contatto:
      • Marseille, Francia
        • Reclutamento
        • Assistance Publique - Hôpitaux de Marseille
        • Contatto:
      • Nancy, Francia
        • Reclutamento
        • CHRU De Nancy
        • Contatto:
      • Paris, Francia
      • Strasbourg, Francia

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 4 anni a 25 anni (Bambino, Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histologically proven diagnosis of ependymoma or medulloblastoma
  • Methyloma classification performed or available material for methyloma analysis
  • Confirmed progressive or refractory disease despite standard therapy, or for which no effective standard therapy exists
  • Male and female subjects with > 4 to ≤ 25 years of age at inclusion
  • Weight > 20 kg
  • Evaluable target lesion(s) according to RAPNO
  • Performance status: Karnofsky performance status (for patients >12 years of age) or Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to walk because of paralysis or stable neurological disability, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  • Life expectancy ≥ 3 months
  • No known allergy to any of the compounds in the experimental treatment
  • Able to take oral treatments
  • Adequate organ function:

Hematologic criteria

  • Peripheral absolute neutrophil count (ANC) ≥ 1000/mm3 (unsupported)
  • Platelet count ≥ 100,000/mm3 (unsupported)
  • Hemoglobin ≥ 8.0 g/dL (transfusion is allowed) Cardiac function
  • Shortening fraction (SF) >29% and left ventricular ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography (mandatory only for patients who have received cardiotoxic therapy).

Renal and hepatic function

  • Serum creatinine < 1.5 x upper limit of normal (ULN) for age

  • Total bilirubin < 1.5 x ULN

  • Alanine aminotransferase (ALT)/ Aspartate aminotransferase (AST)/ < 2.5 x ULN

    • Able to comply with scheduled follow-up and with management of toxicity.
    • Females of child bearing potential must have a negative serum pregnancy test within 7 days prior to initiation of treatment.
    • Sexually active patients must agree to use adequate and appropriate contraception (in accordance with Clinical Trials Facilitation and Coordination Group (CTFG) recommendations) while on study drug and for 6 months after stopping the study drug.
    • Patient able to comfortably swallow capsules.
    • Written informed consent from parents/legal representative, patient, and age-appropriate assent before any study-specific screening procedures are conducted according to local, regional or national guidelines.
    • Patient affiliated to a social security regimen or beneficiary of the same according to local requirements.

Non-inclusion Criteria

  • Chemotherapy within 21 days of day 1 from the start of study treatment. This period can be shortened in the case of treatment with vincristine (2 weeks) and extended to 6 weeks in the case of treatment with nitrosureas. The period is set to 5 half-lives in the case of targeted therapies or metronomic chemotherapy. The period is set to 2 weeks after bevacizumab administration. Evidence of > Grade 1 recent CNS hemorrhage on the baseline MRI or scan.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome).
  • Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
  • Known active viral hepatitis or known human immunodeficiency virus (HIV) infection or any other uncontrolled infection.
  • Presence of any NCI-CTCAE v5 grade ≥ 2 treatment-related extra-hematological toxicity with the exception of alopecia, ototoxicity or peripheral neuropathy.
  • Known congenital immunodeficiency.
  • Radiotherapy within the 2 months preceding D1 of the start of study treatment. Palliative RT on a non-target lesion is allowed up to 1 weeks before beginning of treatment.
  • Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of the investigational drug is administered.
  • Bleeding disorder.
  • Clinically significant, uncontrolled heart disease (including history of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening).
  • Known hypersensitivity to any study drug or component of the formulation.
  • Absence of effective contraception in patients of childbearing age (see appendix 3)
  • Pregnant or nursing (lactating) females.
  • Patients with galactose intolerance, lactase deficiency or glucose or galactose malabsorption syndrome (rare hereditary diseases).
  • Severe infections requiring parenteral antibiotic therapy.
  • Inability to undergo medical monitoring of the trial for geographic, social or psychological reasons.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Patients receiving axitinib in combination with etoposide
  1. st stage: Dose escalation The first patient will be included at the level of 1.6 mg/m²/day of axitinib. Patients will be included by cohort of a maximum of 6 patients evaluable for DLT. In the absence of more than 2 patients with DLT during the first 28-day cycle, escalation to the next level will be allowed. Intra-patient dose escalation is not permitted. Non evaluable patients for DLT will be replaced. Six evaluable patients will be enrolled at the last dose level. RP2D will be the DMT or in the absence of DLT the maximum dose evaluated.

    Treatment will be continued until progression, or unacceptable toxicity for a period of 1 year.

    Depending on the number of DLTs observed, a maximum of 18 patients should be included.

  2. nd stage: extension cohort For the second phase of the study, at RP2D, 2 cohorts of 9 patients (ependymoma, medulloblastoma) will be considered in the study. Treatment will be continued until progression, or unacceptable toxicity for a period of 1 year.

  1. st stage:

    • Axitinib (Inlyta®) PO, in the morning and in the evening every day
    • Level -1 : Dose 1.2 mg/m²
    • Level 1: Dose 1.6 mg/m²
    • Level 2: Dose 2.0 mg/m²
    • Level 3: Dose 2.4 mg /m² (equivalent to 4 mg in adults)
    • Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m²/day in the evening orally every day fasting (capped to a maximum of 50 mg/day) First patient will be enrolled at dose level 1
  2. nd stage:

    • Axitinib (Inlyta®) dosing as selected at the 1st stage
    • Etoposide (50 mg capsules or in the form of etoposide phosphate if required): 25 mg/m2/ day in the evening orally every day fasting(capped to a maximum of 50 mg/day)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Dose-limiting toxicity (DLT)
Lasso di tempo: During the first 28 days (cycle 1)

During first stage

During the first 28 days (cycle 1)
Progression-free survival (PFS)
Lasso di tempo: 3 years (from start of treatment to last follow-up visit)

During second stage, progression-free survival (PFS) computed as the time interval from the beginning of treatment to the date of centrally-assessed with RAPNO criteria. A central review of all imaging is planned at the end of phase 1 and at the end of phase expansion to evaluate tumor response and progressions. PFS-duration of patients alive free of progression at last follow-up will be censored at the date of last visit.

3 years (from start of treatment to last follow-up visit)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Nicolas ANDRE, Assistance Publique - Hôpitaux de Marseille

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 febbraio 2032

Completamento primario (Stimato)

1 febbraio 2032

Completamento dello studio (Stimato)

1 febbraio 2032

Date di iscrizione allo studio

Primo inviato

25 giugno 2024

Primo inviato che soddisfa i criteri di controllo qualità

2 luglio 2024

Primo Inserito (Effettivo)

3 luglio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi